2080 Century Park E #803 Los Angeles, CA 90067
M-F, 8:30 AM to 5:00 PM
Founded by Dr. David Berz, a leading medical oncologist, Valkyrie Clinical Trials, with a mission of providing access to the most effective cancer therapies to patients of all backgrounds. The company owns and operates a cutting-edge research site in Century City and additionally provides a variety of clinical, research, and site management services.
Founded by Dr. David Berz, a leading medical oncologist, Valkyrie Clinical Trials, with a mission of providing access to the most effective cancer therapies to patients of all backgrounds. The company owns and operates a cutting-edge research site in Century City and additionally provides a variety of clinical, research, and site management services.
Dr. Berz is the best doctor! He saved my life. I came to Dr. Berz after diagnosed with NSCLC (stage 4) three weeks ago, in a bad condition. He patiently listened to me and answered all questions I had. Then, he took time to explain about my cancer and prescribed a targeted mutation therapy for me. After taking it for three weeks, my shortness of breath, hoarseness, and tiredness are gone! I will continue taking the medication and will have follow up appointments, but I am feeling much better now. I cannot thank him and his staff enough, especially Jennifer, Debbie, and Helena!
An Nguyen
Dr. Berz is unlike ANY other medical doctor we have ever come across in our lives!! After learning our father had NSCLC (stage 4), we were informed that the recommended plan of action was to proceed with hospice, offering little to no answers from the original doctor that left our family feeling completely hopeless, scared, and so confused. Dr. Berz was literally our miracle of hope. After speaking with him, he gave us a very detailed description of the different options and we were notified that there was a targeted mutation therapy that our father was an ideal candidate for!! In just a couple of weeks, we have seen a noticeable improvement in so many ways! We are so grateful to Dr. Berz for the opportunity to access this treatment and for exhibiting such a warm and loving demeanor toward our family. We cannot thank him and his staff enough!
Jacqueline Rios
I have been a patient of DR DAVID BERZ for the past 7 years and I must say he is the BEST OF THE BEST . I could not have come so far without his help and work he provides. Oh and let me tell you about his staff they are awesome always there when you need them; they get the job done with a smile 😃. Well done you guys.
Kisha Wilson
I have been a patient of doctor Berz for the last 5 years he’s a great doctor I like the way he explains everything. I lost contact with him for 6 month until I found his new location I’m very happy that I found him and his staff members are all nice, friendly & very polite
Nellie Zamora
CAR T-Cell Therapy: A Paradigm Shift in Leukemia and Lymphoma Care Explore the mechanism of action and development of chimeric antigen receptor (CAR) T-cell therapy for leukemia and lymphoma. Learn about the engineering of CAR T-cells to recognize and target specific antigens on cancer cells, leading to potent antitumor immune responses. Clinical Efficacy and Safety […]
Targeted Therapies and Immunotherapy in Lung Cancer Treatment Explore the different types of lung cancer and their prevalence, including non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Gain insights into the risk factors, symptoms, and diagnostic methods used in lung cancer detection and diagnosis. Breakthroughs in Targeted Therapies Discover the latest breakthroughs […]
Advancements in Glioblastoma Research: Future Directions Gain insights into the current understanding of glioblastoma, the most aggressive primary brain tumor in adults. Explore recent advancements in glioblastoma research, including genomic profiling, molecular subtyping, and the identification of therapeutic targets. Novel Therapeutic Strategies Discover novel therapeutic strategies emerging in glioblastoma research, such as immunotherapy, targeted therapies, […]
SER ISD1-001
This study will evaluate the feasibility of optimizing the safety and tolerability of serabelisib (an investigational PI3K inhibitor) when combined with an ISD and with or without nab-paclitaxel with a goal of reducing side effects and enhancing anticancer activity.
BI 1480-0001
This study is open to adults with different types of advanced cancer. People can take part if previous treatment was not successful, or no treatment exists.
The purpose of this study is to find the highest dose of a medicine called BI 1703880 that people with advanced cancer can tolerate when taken together with ezabenlimab. BI 1703880 and ezabenlimab are medicines that may help the immune system fight cancer. In this study, BI 1703880 is given to people for the first time.
Participants get BI 1703880 and ezabenlimab as infusions into a vein. During the first 6 weeks, they get BI 1703880 once a week. Later, they get BI 1703880 every 3 weeks. After the first 3 weeks, they get ezabenlimab in addition every 3 weeks.
Participants can get BI 1703880 for up to 1 year and ezabenlimab for up to 2 years as long as they benefit from treatment and can tolerate it. During this time, they visit the study site regularly. At these visits, the doctors check participants’ health and take note of any unwanted effects.
BGB-16673-101
Study consists of two main parts to explore BGB-16673 recommended dosing, a Part 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a part 2 (dose expansion cohorts).
BGB-3111-308
The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R^2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL), as measured by progression-free survival as determined by an independent review committee in accordance with the 2014 modification of the International Working Group on non-Hodgkin lymphoma (NHL) Criteria based on n positron emission tomography and computed tomography (PET/CT), and to compare the efficacy of zanubrutinib plus rituximab versus R^2 in participants with R/R marginal zone lymphoma (MZL), as measured by progression free survival (PFS) assessed by IRC in accordance with CT-based Lugano 2014 Criteria.
BI 1412-0003
This study is open to adults with advanced colorectal cancer or with advanced pancreatic cancer. The study has 2 parts. In the first part, participants with colorectal cancer get a medicine called BI 905711 combined with chemotherapy and bevacizumab. The purpose of the first part is to find the highest BI 905711 dose participants can tolerate. In the second part, participants with colorectal cancer or pancreatic cancer get BI 905711 combined with chemotherapy. Some participants also get bevacizumab. The second part tests whether BI 905711 makes tumours shrink. Participants get BI 905711, chemotherapy and bevacizumab about every 2 weeks as an infusion into a vein. Participants can stay in the study as long as they benefit from treatment and can tolerate it. The doctors regularly check the health of the participants and note any health problems that could have been caused by the study treatment. The doctors also monitor the size of the tumour.
AdvanTIG-205
This is a randomized investigator and patient blinded, sponsor unblinded, multicenter study that evaluates the safety and efficacy of ociperlimab with tislelizumab and histology-based chemotherapy compared with treatment with tislelizumab and histology-based chemotherapy in participants with previously untreated locally advanced, unresectable, or metastatic NSCLC
BDTX-1535-101
BDTX-1535-101 is a first-in-human, open-label, Phase 1 dose escalation and multiple expansion cohort study designed to evaluate the safety, tolerability, pharmacokinetics (PK), central nervous system (CNS) activity, and preliminary antitumor activity of BDTX-1535. The study population comprises adults with either advanced/metastatic non-small cell lung cancer (NSCLC) harboring sensitive epidermal growth factor receptor (EGFR) mutations with or without CNS disease, or glioblastoma multiforme (GBM) expressing EGFR alterations. All patients will self administer BDTX-1535 monotherapy in 21-day cycles. One expansion cohort will include patients with newly diagnosed GBM who will self administer BDTX-1535 in combination with temozolomide in 28-day cycles.